Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model

So Hee Nam; Jae Hwan Jeong; Xiangguo Che; Kyung Eun Lim; Hyemi Nam; Jong Sang Park; Je Yong Choi

doi:10.1016/j.bone.2011.10.017

Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model

So Hee Nam, Jae Hwan Jeong, Xiangguo Che, Kyung Eun Lim, Hyemi Nam, Jong Sang Park, Je Yong Choi

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

We investigated the therapeutic effect of topical Risedronate (RIS) on a mouse model of estrogen-deficient osteoporosis. Fourteen-week-old female mice were ovariectomized and assigned to 4 groups: SHAM-operated (SHAM), OVX mice treated with vehicle (OVX-V), OVX mice treated with 0.2% RIS (OVX-0.2% RIS), and OVX-mice treated with 0.02% RIS (OVX-0.02% RIS). Topical samples containing RIS were prepared in 10% (w/w) polyethylene glycol (PEG, MW 400) and 80. μg of sample was spread on the mice's mid-backs every 3. days for 5. weeks. Micro-CT analysis of femora demonstrated that OVX-0.2% RIS exhibited a 29% greater bone mineral density and 24% greater bone volume fraction than that of OVX-V group. Investigation of the trabecular bone in OVX-0.2% RIS revealed a 24% higher bone volume (BV/TV), 51% higher trabecular number (Tb.N), and 40% lower trabecular separation (Tb.Sp) compared to OVX-V mice. Additionally, bone phenotypes of tibiae were further confirmed by histological analysis. OVX-0.2% RIS group exhibited a 494% greater BV/TV, 464% less Tb.Sp, 81% greater active osteoclast surface (Oc.S/BS) and 26% less osteoclast number (N.Oc/BS) than that of OVX-V group. Collectively, these results indicated that topical delivery of RIS has powerful pharmaceutical effects on the prevention of osteoporosis and bone turnover.

Original language	English
Pages (from-to)	149-155
Number of pages	7
Journal	Bone
Volume	50
Issue number	1
DOIs	https://doi.org/10.1016/j.bone.2011.10.017
State	Published - Jan 2012

Keywords

Osteoporosis
Ovariectomized mouse model
Risedronate
Topical delivery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bone.2011.10.017

Cite this

@article{959ee0e563a547279935345f41f359ce,

title = "Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model",

abstract = "We investigated the therapeutic effect of topical Risedronate (RIS) on a mouse model of estrogen-deficient osteoporosis. Fourteen-week-old female mice were ovariectomized and assigned to 4 groups: SHAM-operated (SHAM), OVX mice treated with vehicle (OVX-V), OVX mice treated with 0.2% RIS (OVX-0.2% RIS), and OVX-mice treated with 0.02% RIS (OVX-0.02% RIS). Topical samples containing RIS were prepared in 10% (w/w) polyethylene glycol (PEG, MW 400) and 80. μg of sample was spread on the mice's mid-backs every 3. days for 5. weeks. Micro-CT analysis of femora demonstrated that OVX-0.2% RIS exhibited a 29% greater bone mineral density and 24% greater bone volume fraction than that of OVX-V group. Investigation of the trabecular bone in OVX-0.2% RIS revealed a 24% higher bone volume (BV/TV), 51% higher trabecular number (Tb.N), and 40% lower trabecular separation (Tb.Sp) compared to OVX-V mice. Additionally, bone phenotypes of tibiae were further confirmed by histological analysis. OVX-0.2% RIS group exhibited a 494% greater BV/TV, 464% less Tb.Sp, 81% greater active osteoclast surface (Oc.S/BS) and 26% less osteoclast number (N.Oc/BS) than that of OVX-V group. Collectively, these results indicated that topical delivery of RIS has powerful pharmaceutical effects on the prevention of osteoporosis and bone turnover.",

keywords = "Osteoporosis, Ovariectomized mouse model, Risedronate, Topical delivery",

author = "Nam, {So Hee} and Jeong, {Jae Hwan} and Xiangguo Che and Lim, {Kyung Eun} and Hyemi Nam and Park, {Jong Sang} and Choi, {Je Yong}",

year = "2012",

month = jan,

doi = "10.1016/j.bone.2011.10.017",

language = "English",

volume = "50",

pages = "149--155",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model

AU - Nam, So Hee

AU - Jeong, Jae Hwan

AU - Che, Xiangguo

AU - Lim, Kyung Eun

AU - Nam, Hyemi

AU - Park, Jong Sang

AU - Choi, Je Yong

PY - 2012/1

Y1 - 2012/1

N2 - We investigated the therapeutic effect of topical Risedronate (RIS) on a mouse model of estrogen-deficient osteoporosis. Fourteen-week-old female mice were ovariectomized and assigned to 4 groups: SHAM-operated (SHAM), OVX mice treated with vehicle (OVX-V), OVX mice treated with 0.2% RIS (OVX-0.2% RIS), and OVX-mice treated with 0.02% RIS (OVX-0.02% RIS). Topical samples containing RIS were prepared in 10% (w/w) polyethylene glycol (PEG, MW 400) and 80. μg of sample was spread on the mice's mid-backs every 3. days for 5. weeks. Micro-CT analysis of femora demonstrated that OVX-0.2% RIS exhibited a 29% greater bone mineral density and 24% greater bone volume fraction than that of OVX-V group. Investigation of the trabecular bone in OVX-0.2% RIS revealed a 24% higher bone volume (BV/TV), 51% higher trabecular number (Tb.N), and 40% lower trabecular separation (Tb.Sp) compared to OVX-V mice. Additionally, bone phenotypes of tibiae were further confirmed by histological analysis. OVX-0.2% RIS group exhibited a 494% greater BV/TV, 464% less Tb.Sp, 81% greater active osteoclast surface (Oc.S/BS) and 26% less osteoclast number (N.Oc/BS) than that of OVX-V group. Collectively, these results indicated that topical delivery of RIS has powerful pharmaceutical effects on the prevention of osteoporosis and bone turnover.

AB - We investigated the therapeutic effect of topical Risedronate (RIS) on a mouse model of estrogen-deficient osteoporosis. Fourteen-week-old female mice were ovariectomized and assigned to 4 groups: SHAM-operated (SHAM), OVX mice treated with vehicle (OVX-V), OVX mice treated with 0.2% RIS (OVX-0.2% RIS), and OVX-mice treated with 0.02% RIS (OVX-0.02% RIS). Topical samples containing RIS were prepared in 10% (w/w) polyethylene glycol (PEG, MW 400) and 80. μg of sample was spread on the mice's mid-backs every 3. days for 5. weeks. Micro-CT analysis of femora demonstrated that OVX-0.2% RIS exhibited a 29% greater bone mineral density and 24% greater bone volume fraction than that of OVX-V group. Investigation of the trabecular bone in OVX-0.2% RIS revealed a 24% higher bone volume (BV/TV), 51% higher trabecular number (Tb.N), and 40% lower trabecular separation (Tb.Sp) compared to OVX-V mice. Additionally, bone phenotypes of tibiae were further confirmed by histological analysis. OVX-0.2% RIS group exhibited a 494% greater BV/TV, 464% less Tb.Sp, 81% greater active osteoclast surface (Oc.S/BS) and 26% less osteoclast number (N.Oc/BS) than that of OVX-V group. Collectively, these results indicated that topical delivery of RIS has powerful pharmaceutical effects on the prevention of osteoporosis and bone turnover.

KW - Osteoporosis

KW - Ovariectomized mouse model

KW - Risedronate

KW - Topical delivery

UR - http://www.scopus.com/inward/record.url?scp=80355125351&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2011.10.017

DO - 10.1016/j.bone.2011.10.017

M3 - Article

C2 - 22036912

AN - SCOPUS:80355125351

SN - 8756-3282

VL - 50

SP - 149

EP - 155

JO - Bone

JF - Bone

IS - 1

ER -

Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this